Johnson & Johnson on Tuesday announced that it would stop selling its talc-based Johnson's Baby Powder in the United States and Canada, making the decision after a consumer products "portfolio reassessment related to Covid-19."

The US healthcare conglomerate said it would wind down sales of the product, which makes up about 0.5 percent of its US consumer health business, in the coming months, but that retailers will continue to sell existing inventory.